{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-102611","form_type":"8-K","ticker":"LGVN","cik":"0001721484","company_name":"Longeveron Inc.","filed_at":"2026-09-23T20:01:32+00:00","discovered_at":"2026-09-23T20:02:10.543679+00:00","generated_at":"2026-09-23T20:02:25.191400+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Longeveron's ELPIS II Phase 2b misses primary endpoint; strategic review initiated","bullets":["ELPIS II missed primary endpoint: RVEF change from baseline -0.7 pp (95% CI -7.3 to 5.9, p=0.8336) in ITT.","Exploratory: no deaths in laromestrocel arm vs 1 control at 12 months; transplant-free survival 1 vs 2 events.","MACE ~31% fewer (12 vs 19 events) but not statistically significant; no new safety signals across 644 patients.","Company to explore all options to maximize shareholder value, engaging an investment bank and cost containment.","Longevity/frailty: Phase 2b data published in Cell Stem Cell Feb 2026; $1M XPRIZE Milestone 2 Award, up to $81M grand prize."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-102611","json":"https://secwatch.observer/filing/0001213900-26-102611.json","markdown":"https://secwatch.observer/filing/0001213900-26-102611.md","text":"https://secwatch.observer/filing/0001213900-26-102611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/0001213900-26-102611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/ea0306147-8k_longeveron.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T20:02:25.191400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}